Identification of Gene Expression Signatures for Phenotype-Specific Drug Targeting of Cardiac Fibrosis - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue International Journal of Molecular Sciences Année : 2023

Identification of Gene Expression Signatures for Phenotype-Specific Drug Targeting of Cardiac Fibrosis

Résumé

We have designed translational animal models to investigate cardiac profibrotic gene signatures. Domestic pigs were treated with cardiotoxic drugs (doxorubicin, DOX, n = 5 or Myocet®, MYO, n = 5) to induce replacement fibrosis via cardiotoxicity. Reactive interstitial fibrosis was triggered by LV pressure overload by artificial isthmus stenosis with stepwise developing myocardial hypertrophy and final fibrosis (Hyper, n = 3) or by LV volume overload in the adverse remodeled LV after myocardial infarction (RemoLV, n = 3). Sham interventions served as controls and healthy animals (Control, n = 3) served as a reference in sequencing study. Myocardial samples from the LV of each group were subjected to RNA sequencing. RNA-seq analysis revealed a clear distinction between the transcriptomes of myocardial fibrosis (MF) models. Cardiotoxic drugs activated the TNF-alpha and adrenergic signaling pathways. Pressure or volume overload led to the activation of FoxO pathway. Significant upregulation of pathway components enabled the identification of potential drug candidates used for the treatment of heart failure, such as ACE inhibitors, ARB, ß-blockers, statins and diuretics specific to the distinct MF models. We identified candidate drugs in the groups of channel blockers, thiostrepton that targets the FOXM1-regulated ACE conversion to ACE2, tyrosine kinases or peroxisome proliferator-activated receptor inhibitors. Our study identified different gene targets involved in the development of distinct preclinical MF protocols enabling tailoring expression signature-based approach for the treatment of MF.
Fichier principal
Vignette du fichier
ijms-24-07461.pdf (3.56 Mo) Télécharger le fichier
ijms-24-07461-s001.zip (4.47 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence
Licence

Dates et versions

hal-04087640 , version 1 (03-05-2023)

Licence

Identifiants

Citer

Dominika Lukovic, Ena Hasimbegovic, Johannes Winkler, Julia Mester-Tonczar, Katrin Müller-Zlabinger, et al.. Identification of Gene Expression Signatures for Phenotype-Specific Drug Targeting of Cardiac Fibrosis. International Journal of Molecular Sciences, 2023, 24 (8), pp.7461. ⟨10.3390/ijms24087461⟩. ⟨hal-04087640⟩
30 Consultations
35 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More